empagliflozin
boehringer ingelheim
['cardio', 'empa-kidney']
data from empa-kidney and a new meta-analysis of large sglt2i trials show the drug class reduces ckd progression, cv risk and hospitalization in people with and without #t2d #aha22 #cardiotwitter 
The content you need, when you need it.